Teva Pharmaceuticals’ June 25 approval of its generic phentermine and topiramate extended-release tablets introduces a likely price-competitive alternative to the branded Qsymia, positioning the company to capture significant market share in the weight management sector. This entry intensifies pricing pressure on competitors, potentially shifting revenue streams from label exclusivity holders to generic manufacturers.